Literature DB >> 4812149

Procainamide-induced SLE and lymphoreticular disorders.

B Artinian, M Reesal.   

Abstract

A 56-year-old male patient diagnosed as a case of procainamide-induced systemic lupus erythematosus (SLE) was found to have a lymphoproliferative disorder at postmortem examination.Contrary to other immune disorders, the association of SLE with neoplasia is a rare occurrence. The present case raises the question of whether a relationship exists between the lupus diathesis and lymphoreticular neoplasia. The study of the incidence of neoplasia in families of patients with SLE may prove helpful in establishing this relationship.

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4812149      PMCID: PMC1947260     

Source DB:  PubMed          Journal:  Can Med Assoc J        ISSN: 0008-4409            Impact factor:   8.262


  10 in total

1.  L.E. CELLS IN LYMPHOMA.

Authors:  J HOWQUA; I R MACKAY
Journal:  Blood       Date:  1963-08       Impact factor: 22.113

2.  Systemic rheumatic disease and malignant lymphoma.

Authors:  R J CAMMARATA; G P RODNAN; W N JENSEN
Journal:  Arch Intern Med       Date:  1963-03

3.  Studies of relatives of patients with systemic lupus erythematosus.

Authors:  O G MORTEO; E C FRANKLIN; C MCEWEN; J PHYTHYON; M TANNER
Journal:  Arthritis Rheum       Date:  1961-08

4.  Appearance of Hodgkin's disease in a patient with systemic lupus erythematosus.

Authors:  L B Nilsen; M E Missal; J J Condemi
Journal:  Cancer       Date:  1967-11       Impact factor: 6.860

5.  Type I dysgammaglobulinemia, systemic lupus erythematosus and lymphoma.

Authors:  C K Smith; J T Cassidy; G G Bole
Journal:  Am J Med       Date:  1970-01       Impact factor: 4.965

6.  Procainamide-induced lupus erythematosus. Clinical and laboratory observations.

Authors:  S E Blomgren; J J Condemi; J H Vaughan
Journal:  Am J Med       Date:  1972-03       Impact factor: 4.965

7.  The association of immune disease and malignant lymphoma.

Authors:  D G Miller
Journal:  Ann Intern Med       Date:  1967-03       Impact factor: 25.391

Review 8.  Drug-induced lupus syndromes.

Authors:  D Alarcón-Segovia
Journal:  Mayo Clin Proc       Date:  1969-09       Impact factor: 7.616

9.  Malignant lymphomas following allogenic disease: transition from an immunological to a neoplastic disorder.

Authors:  R S Schwartz; L Beldotti
Journal:  Science       Date:  1965-09-24       Impact factor: 47.728

10.  Malignant tumours following immunosuppressive therapy.

Authors:  K P Pritzker; S N Huang; K G Marshall
Journal:  Can Med Assoc J       Date:  1970-12-19       Impact factor: 8.262

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.